Spots Global Cancer Trial Database for mln341
Every month we try and update this database with for mln341 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | NCT00810576 | Lymphoma | Vorinostat Bortezomib | 18 Years - | M.D. Anderson Cancer Center | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy | NCT00428545 | Advanced Malign... Lymphoma Myeloma Solid Tumors | Bevacizumab Bortezomib | - | M.D. Anderson Cancer Center | |
| Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | NCT00059631 | Prostate Cancer | Mitoxantrone (N... Bortezomib (PS-... | 18 Years - | M.D. Anderson Cancer Center | |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | NCT00059618 | Ovarian Cancer Primary Periton... Fallopian Tube ... | PS-341 (Bortezo... Carboplatin | - | M.D. Anderson Cancer Center | |
| Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | NCT00479128 | Solid Tumor Urethral Cancer | Bortezomib Gemcitabine Doxorubicin | - | M.D. Anderson Cancer Center | |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | NCT01531998 | Myeloma | Lenalidomide Bortezomib Siltuximab Dexamethasone Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation | NCT01891968 | Leukemia | Bortezomib | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | NCT01440582 | Myeloma | Panobinostat Bortezomib Lenalidomide Dexamethasone Symptom Questio... | 18 Years - | M.D. Anderson Cancer Center | |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | NCT00059618 | Ovarian Cancer Primary Periton... Fallopian Tube ... | PS-341 (Bortezo... Carboplatin | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
